Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 06 2021 - 9:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 6 April 2021, London UK
GSK announces Dr Anne Beal to join the Board as Non-Executive
Director
GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Dr Anne
Beal will join the Board of the Company as a Non-Executive Director
with effect from 6 May 2021.
On joining the Board, Dr Beal will become a member of the Corporate
Responsibility Committee (the 'Committee') which provides important
oversight of the Company's Trust agenda including policies towards
access to medicines, global health, inclusion and diversity and
environmental sustainability. Dr Beal will succeed Lynn Elsenhans
as Chair of the Committee after the 2022 Annual General Meeting. Ms
Elsenhans has agreed to remain on the Board for a further year to
facilitate an orderly transition to Dr Beal's leadership of the
Committee.
Dr Beal will bring to GSK extensive healthcare experience as a
physician and entrepreneur combined with a passion for patient
advocacy. She is a recognised health policy expert in the
development of global and national programmes for improving
healthcare access for all patient groups and in ensuring the voice
of patients is reflected in research programmes.
Commenting on the changes, Sir Jonathan Symonds, Chairman of GSK
said: "I am delighted to welcome Anne to GSK. Acting responsibly is
an integral part of how successful modern businesses deliver for a
wide range of stakeholders including investors. That's why the work
of the Corporate Responsibility Committee is critical to the
success of GSK. Anne's expertise and experience will be a valuable
addition to GSK and to the leadership of the Committee. I would
like to thank Lynn for her service to the Company over the last
nine years and to agreeing to stay on to ensure a smooth transition
to Anne."
Dr Beal is founder and CEO of AbsoluteJOI Skincare and a member of
the Board of AcademyHealth. Prior to her current roles, Dr Beal
spent six years at Harvard Medical School and Massachusetts General
Hospital, where she was an instructor in paediatrics and has also
held leadership roles at the Commonwealth Fund and the Aetna
Foundation. In addition, Dr Beal was previously Deputy Executive
Director and Chief Engagement Officer for The Patient-Centered
Outcomes Research Institute in the U.S. and Chief Patient Officer
and Global Head of Patient Solutions at Sanofi.
She holds a B.A. from Brown University, an M.D. from Cornell
University Medical College, and an M.P.H. from Columbia
University.
Notes
1.
|
The appointment of Dr Anne Beal was made by the Board on the
recommendation of the Nominations & Corporate Governance
Committee.
|
2.
|
The Board has determined that Dr Beal will be an independent
Non-Executive Director on appointment in accordance with the UK
Corporate Governance Code.
|
3.
|
Dr Beal will receive the standard basic fee for a Non-Executive
Director of £95,000 per annum. She will receive a further
payment of £40,000 per annum when she succeeds Ms Elsenhans as
Chair of the Corporate Responsibility Committee.
Dr Beal will be required to invest at least 25% of her fees in GSK
shares that should be held until her retirement from the
Board.
|
4.
|
Membership of other Committees will be determined in due
course.
|
5.
|
Dr Beal does not have a service contract. She has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
|
6.
|
There are no additional details to disclose in respect of Dr Beal's
appointment under Listing Rule 9.6.13R.
|
7.
|
From 6 May 2021 the Board of GSK will comprise:
|
|
Sir Jonathan Symonds
Emma
Walmsley
Iain
Mackay
Dr Hal Barron
Vindi Banga
Charles Bancroft
Dr Anne Beal
Dr Vivienne
Cox
Lynn
Elsenhans
Dr Jesse Goodman
Dr Laurie Glimcher
Urs
Rohner
|
Non-Executive Chairman
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer and President, R&D
Senior Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
|
|
As previously announced, Charles Bancroft has succeeded Judy Lewent
as Chair of the Audit & Risk Committee following approval of
GSK's 2020 Annual Report. Judy will not stand for re-election to
the Board at GSK's Annual General Meeting on 5 May
2021.
Lynn Elsenhans will stand for re-election at the AGM and remain on
the Board for a further year to facilitate a smooth handover to Dr
Beal.
|
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
GSK enquiries:
|
|
|
|
Media enquiries:
|
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
Madeleine Breckon
|
+44 (0) 7880 040 329
|
(London)
|
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
|
|
|
|
|
Analyst/Investor enquiries:
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2020 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: April
06, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024